Conditions: Non-small Cell Lung Cancer Stage IIIC; Non-small Cell Lung Cancer Stage IV; Non Small Cell Lung Cancer; Non-small Cell Lung Cancer Metastatic; Non-small Cell Lung Cancer Unresectable
Interventions: Drug: Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.; Drug: Standard of Care
Sponsors: University of California, Davis; National Cancer Institute (NCI)
Not yet **RECRUITING NOW**
Interventions: Drug: Systemic (ICI)-based therapy informed by the PROphet CB assay and the CARG-TT assessment.; Drug: Standard of Care
Sponsors: University of California, Davis; National Cancer Institute (NCI)
Not yet **RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
